

Lumvoa™ (veligrotug-vvze)

When requesting Lumvoa™ (veligrotug-vvze), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Lumvoa is indicated for the treatment of thyroid eye disease, regardless of thyroid eye disease activity or duration.

Coverage Guidelines

Thyroid Eye Disease (Note: Also recognized as Graves' ophthalmopathy, Graves' orbitopathy, thyroid-associated ophthalmopathy, and thyroid orbitopathy)

The individual must meet **ALL** of the following criteria for approval:

- Is 18 years of age or older;
- Has been assessed as having at least moderate severity level of disease based on signs and symptoms;
Note: Examples of signs and symptoms of disease of at least moderate severity include the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, proptosis ≥ 3 mm above normal for race and sex, and diplopia (Gorman Score 2 to 3).
- Has not received a total of five infusions of Lumvoa;
Note: The maximum recommended treatment is for five doses.
- Lumvoa is prescribed by or in consultation with an ophthalmologist, endocrinologist, or a physician who specializes in thyroid eye disease.

Approval duration: 6 months

Dosing Recommendations

The recommended dose of Lumvoa is an intravenous infusion of 10 mg/kg every three weeks for a total of 5 infusions.

References

1. Lumvoa intravenous infusion [prescribing information]. Waltham, MA: Viridian; June 2026.
2. Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. *Thyroid*. 2022;32(12):1439-1470.
3. Tepezza intravenous infusion [prescribing information]. Dublin, Ireland: Horizon and Thousand Oaks, CA: Amgen; November 2025.